William G. Wierda, Thomas J. Kipps, Michael J. Keating, Jennifer R. Brown, John G. Gribben, Mary Browning, Laura Z. Rassenti, Andrew W. Greaves, Donna Neuberg, Susan M. O'Brien and and the CLL Research Consortium Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia Cancer 117
Article first published online: 30 AUG 2010 | DOI: 10.1002/cncr.25379
The results from this study demonstrated that self-administered, subcutaneous alemtuzumab was safe and active for residual disease and that plasma alemtuzumab levels and real-time minimal residual disease evaluation are important endpoints to monitor in alemtuzumab consolidation trials.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field